REALM
DEAD

Serial Number

97933294

Owner

REALM IDX, INC.

Attorney

Carrie L. Kiedrowski

Filing Date

May 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

REALM Trademark

Serial Number: 97933294

REALM is a trademark filed by REALM IDX, INC. on May 12, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

REALM IDX, INC. (15 trademarks)

ALISO VIEJO, CA 92656

Entity Type: 03

Trademark Details

Filing Date

May 12, 2023

Registration Date

Not Registered

Goods & Services

Research and development in the fields of personalized medicine and diagnostics; data mining of healthcare and genetic information in the field of precision medicine and personalized medicine; scientific study and research in the fields of biochemistry, disease, personalized medicine, personalized therapeutics, and/or pharmaceuticals; clinical and medical laboratory testing services in the fields of disease diagnostics and personalized medicine; pharmaceutical drug research and development; custom assay development; pharmaceutical drug discovery and development services; providing laboratory research services in the field of medical diagnostics and personalized medicine; medical research services; biotechnology research; providing medical and scientific research information in the field of clinical trials; research and development of vaccines and therapeutics; data collection services for scientific research purposes in the fields of genomics, healthcare and precision medicine; pharmaceutical research in connection with human genetics and programmable biology; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research in the fields of pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research in the field of treatment of infectious, deficiency, hereditary, and physiological diseases; medical research in connection with various diseases and disorders, including eosinophilic diseases, asthma, CRS, and allergic rhinitis, autoimmune diseases, including psoriasis, vitiligo, and lichen planus, ocular diseases, including intraocular pressure and glaucoma, and atopic dermatitis; scientific, technological, research services for collecting, analyzing, monitoring, reporting or tracking data and information in the fields of physiology, biology, genetics, genomics, metagenomics, microbiome, metabolomics, proteomics, glycomics or biochemistry; scientific, technological, research services for collecting, analyzing, monitoring, reporting or tracking data and information in relation to probiotics, prebiotics or nutraceutical supplements; scientific, technological, research services for collecting, analyzing, monitoring, reporting or tracking data and information in relation to health, wellness, physical well-being, mental well-being, exercise, weight planning or weight management; scientific, technological, research services for collecting, analyzing, monitoring, reporting or tracking data and information in relation to diet, food or nutrition; scientific, technological, research services for collecting, analyzing, monitoring, reporting or tracking data and information in relation to sleep, exercise or consciousness; scientific, technological, research services in the fields of physiology, biology, genetics, genomics, metagenomics, microbiome, metabolomics, proteomics, glycomics or biochemistry; scientific, technological, research services in relation to health, wellness, physical well-being, mental well-being, exercise, weight planning or weight management; scientific, technological, research services in relation to diet, food or nutrition; scientific, technological, research services in relation to sleep, exercise or consciousness

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 30, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 30, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 7, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 13, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2023 NWOS
NEW APPLICATION ENTERED
May 16, 2023 NWAP